Table 2 Baseline characteristics of the study population
| Demographics |
Total (n = 135) |
FMS/RSV (n = 46) |
FMS (n = 45) |
RSV (n = 44) | P-value |
|---|---|---|---|---|---|
| Age (year) | 60.5 (8.7) | 59.3 (8.7) | 62.3 (9.5) | 59.9 (7.7) | 0.137a |
| Sex, men, n (%) | 99 (73.3) | 31 (67.4) | 34 (75.6) | 34 (77.3) | 0.524b |
| Body mass index (kg/m2) | 25.6 (2.7) | 26.4 (2.8) | 25.1 (2.6) | 25.4 (2.8) | 0.033a |
| Baseline blood pressure, mmHg | |||||
| Systolic | 152.8 (9.5) | 152.5 (9.9) | 151.3 (9.0) | 154.7 (9.5) | 0.157a |
| Diastolic | 89.4 (9.1) | 89.4 (8.3) | 85.8 (9.3) | 93.1 (8.5) | 0.001a |
| Baseline Pulse Rate (beats/min) | 75.2 (12.1) | 76.4 (13.1) | 73.0 (10.9) | 76.2 (12.3) | 0.441a |
| Baseline LDL-C (mg/dL) | 165.7 (34.6) | 171.3 (36.0) | 164.1 (39.6) | 161.4 (26.7) | 0.294a |
| Smoking, n (%) | |||||
| Current Smoker | 37 (27.4) | 14 (30.4) | 12 (26.7) | 11 (25.0) | 0.933b |
| Non-smoker | 57 (42.2) | 17 (37.0) | 2 0 (44.4) | 20 (45.5) | |
| Ex-smoker | 41 (30.4) | 15 (32.6) | 13 (28.9) | 13 (29.6) | |
| Drinking, n (%) | |||||
| Current drinker | 83 (61.5) | 30 (65.2) | 27 (60.0) | 26 (59.1) | 0.811b |
| Non-drinker | 52 (38.5) | 16 (34.8) | 18 (40.0) | 18 (40.9) | |
| Medication history of cardiovascular system, n (%) | |||||
| Lipid modifying agents | 93 (68.9) | 31 (67.4) | 34 (75.6) | 28 (63.6) | |
| ACE inhibitors or ARBs | 81 (60.0) | 28 (60.9) | 29 (64.4) | 24 (54.6) | |
| Calcium channel blockers | 38 (28.2) | 9 (19.6) | 13 (28.9) | 16 (36.4) | |
| Beta blockers | 10 (7.4) | 1 (2.2) | 4 (8.9) | 5 (11.4) | |
| Cardiac drugs | 7 (5.2) | - | 5 (11.1) | 2 (4.6) | |
| Diuretics | 5 (3.7) | 1 (2.2) | 2 (4.4) | 2 (4.6) | |
| Peripheral vasodilators | 4 (3.0) | 1 (2.2) | 3 (6.7) | - | |
| Vasoprotectives | 1 (0.7) | - | - | 1 (2.3) | |
| Medical history, n (%) | |||||
| Diabetes mellitus | 33 (24.4) | 8 (17.4) | 16 (35.6) | 9 (20.5) | |
| Angina pectoris | 6 (4.4) | 1 (2.2) | 2 (4.4) | 3 (6.8) |